Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer

NCT02278185 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT02278185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02278185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
November 11, 2015
Completion date
July 18, 2024
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, recurrent prostate cancer, stage iii prostate cancer, stage iv prostate cancer